Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer

作者：Buonerba Carlo; Pond Gregory R; Sonpavde Guru; Federico Piera; Rescigno Pasquale; Puglia Livio; Bosso Davide; Virtuoso Antonella; Policastro Tania; Izzo Michela; Vaccaro Luca; Ferro Matteo; Aieta Michele; Perdona Sisto; Palmieri Giovannella; De Placido Sabino; Di Lorenzo Giuseppe^*

来源：Future Oncology, 2013, 9(6): 889-897.

DOI：10.2217/FON.13.39

• cabazitaxel
• Gleason score
• prostate cancer

Aim: This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel. Patients %26 methods: Patients were enrolled from March 2011 to December 2011 in an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective study was initiated at University Federico II of Naples and at Rionero in Vulture Hospital. Results: Forty-seven patients were enrolled in this study. Patients received a median of nine cycles of cabazitaxel. Median progression-free survival was 7.0 months (95% CI: 5.7-8.0). Seventeen patients were still alive at the time of the analysis, with a median overall survival of 14 months (95% CI: 11-16). At multivariate analysis, a higher Gleason score (%26gt;= 8) appeared to be associated with prolonged progression-free survival (hazard ratio: 0.36; 95% CI: 0.18-0.72); however, the higher Gleason score showed no statistical impact on overall survival. Conclusion: We hypothesize that the Gleason score has the potential to be incorporated in the clinical decision-making process for definition of treatment strategy in docetaxel-pretreated castration-resistant prostate cancer patients. We encourage further experimentation in this setting.

• 出版日期2013-6